Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World

Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell... Adv Ther (2017) 34:2638–2647 DOI 10.1007/s12325-017-0631-7 ORIGINAL RESEARCH Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World . . . Yaimarelis Saumell Lizet Sanchez Sandra Gonzalez . . . Ramo ´ n Ortiz Edadny Medina Yaima Gala ´ n Agustin Lage Received: August 28, 2017 / Published online: November 13, 2017 Springer Healthcare Ltd. 2017 locally advanced or metastatic esophageal ABSTRACT squamous cell carcinoma. Methods: A comparative and retrospective Introduction: Despite improvements in surgi- effectiveness study was performed. The 93 cal techniques and treatments introduced into patients treated with nimotuzumab were mat- clinical practice, the overall survival of patients ched, with use of propensity score matching, with esophageal squamous cell carcinoma with patients who received a diagnosis of locally remains low. Several epidermal growth factor advanced or metastatic squamous cell carci- receptor inhibitors are being evaluated in the noma of the esophagus in three Cuban pro- context of clinical trials, but there is little evi- vinces reported between 2011 and 2015 to the dence of effectiveness in real-world conditions. National Cancer Registry. The Kaplan–Meier This study aimed at assessing the effectiveness method was used to estimate event–time dis- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World

Loading next page...
 
/lp/springer_journal/overall-survival-of-patients-with-locally-advanced-or-metastatic-QsjiQaPOuw
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by Springer Healthcare Ltd.
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0631-7
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial